# Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015

> **NCT00984126** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 214 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A

## Interventions

- **DRUG:** turoctocog alfa
- **DRUG:** turoctocog alfa

## Key facts

- **NCT ID:** NCT00984126
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-26
- **Primary completion:** 2016-06-28
- **Final completion:** 2016-06-29
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2017-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00984126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00984126, "Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00984126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*